These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15340128)

  • 1. The changing face of antibiotic prescribing: the mutant selection window.
    Epstein BJ; Gums JG; Drlica K
    Ann Pharmacother; 2004 Oct; 38(10):1675-82. PubMed ID: 15340128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant selection window hypothesis updated.
    Drlica K; Zhao X
    Clin Infect Dis; 2007 Mar; 44(5):681-8. PubMed ID: 17278059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mutant selection window and antimicrobial resistance.
    Drlica K
    J Antimicrob Chemother; 2003 Jul; 52(1):11-7. PubMed ID: 12805267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window.
    Zhao X; Drlica K
    J Infect Dis; 2002 Feb; 185(4):561-5. PubMed ID: 11865411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach.
    Blondeau JM
    Vet Dermatol; 2009 Oct; 20(5-6):383-96. PubMed ID: 20178475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
    Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
    J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.
    Firsov AA; Smirnova MV; Lubenko IY; Vostrov SN; Portnoy YA; Zinner SH
    J Antimicrob Chemother; 2006 Dec; 58(6):1185-92. PubMed ID: 17028094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW; Neumiller JJ; Setter SM
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibiotic resistance--what's dosing got to do with it?
    Roberts JA; Kruger P; Paterson DL; Lipman J
    Crit Care Med; 2008 Aug; 36(8):2433-40. PubMed ID: 18596628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.
    Zhao X; Drlica K
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S147-56. PubMed ID: 11524712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The mutant selection window in rabbits infected with Staphylococcus aureus.
    Cui J; Liu Y; Wang R; Tong W; Drlica K; Zhao X
    J Infect Dis; 2006 Dec; 194(11):1601-8. PubMed ID: 17083047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.
    Firsov AA; Smirnova MV; Strukova EN; Vostrov SN; Portnoy YA; Zinner SH
    Int J Antimicrob Agents; 2008 Dec; 32(6):488-93. PubMed ID: 18790614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence and spread of antibiotic resistance following exposure to antibiotics.
    Cantón R; Morosini MI
    FEMS Microbiol Rev; 2011 Sep; 35(5):977-91. PubMed ID: 21722146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
    Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
    J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic.
    Matthews SJ; Lancaster JW
    Clin Ther; 2009 Jan; 31(1):42-63. PubMed ID: 19243706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dalbavancin: a new option for the treatment of gram-positive infections.
    Lin SW; Carver PL; DePestel DD
    Ann Pharmacother; 2006 Mar; 40(3):449-60. PubMed ID: 16507624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
    Allen GP; Hankins CD
    J Antimicrob Chemother; 2009 Aug; 64(2):359-63. PubMed ID: 19460783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suicide vectors for antibiotic marker exchange and rapid generation of multiple knockout mutants by allelic exchange in Gram-negative bacteria.
    Ortiz-Martín I; Macho AP; Lambersten L; Ramos C; Beuzón CR
    J Microbiol Methods; 2006 Dec; 67(3):395-407. PubMed ID: 16750581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occurrence of antimicrobial resistance in bacteria from diagnostic samples from dogs.
    Pedersen K; Pedersen K; Jensen H; Finster K; Jensen VF; Heuer OE
    J Antimicrob Chemother; 2007 Oct; 60(4):775-81. PubMed ID: 17644533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faropenem medoxomil.
    Gettig JP; Crank CW; Philbrick AH
    Ann Pharmacother; 2008 Jan; 42(1):80-90. PubMed ID: 18094341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.